Speak directly to the analyst to clarify any post sales queries you may have.
RAC Gamma Serine Threonine Protein Kinase - Pipeline Review, H2 2019
Summary
RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) pipeline Target constitutes close to 9 molecules. The latest report RAC Gamma SerineThreonine Protein Kinase - Pipeline Review, H2 2019, outlays comprehensive information on the RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) - RAC-gamma serine/threonine-protein kinase is an enzyme encoded by the AKT3 gene. AKT3 regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. It plays an important role in brain development and viability of malignant glioma cells. It is required for the coordination of mitochondrial biogenesis with growth factor-induced increases in cellular energy demands. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 5, 2 and 1 respectively. Report covers products from therapy areas Oncology, Hematological Disorders, Non Malignant Disorders and Undisclosed which include indications Endometrial Cancer, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Triple-Negative Breast Cancer (TNBC), Melanoma, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Solid Tumor, Breast Cancer, Fallopian Tube Cancer, Gastric Cancer, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Lung Cancer, Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Pancreatic Cancer, Peritoneal Cancer, Prostate Cancer, Proteus Syndrome, Sickle Cell Disease, Small-Cell Lung Cancer, Thymoma (Thymic Epithelial Tumor), Unspecified Rare Disease and Uterine Cancer.
Furthermore, this report also reviews key players involved in RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Scope
- The report provides a snapshot of the global therapeutic landscape for RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1)
- The report reviews RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
IntroductionReport Coverage
RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) - Overview
RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
ArQule Inc
AstraZeneca Plc
Laekna Therapeutics Shanghai Co Ltd
Merck & Co Inc
Merck KGaA
Novartis AG
Prous Institute for Biomedical Research SA
RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) - Drug Profiles
ARQ-751 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
capivasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JRP-890 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-2698 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
miransertib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-2206 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-2206 + selumetinib sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trametinib dimethyl sulfoxide + uprosertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
uprosertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) - Dormant Products
RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) - Discontinued Products
RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Oct 29, 2019: ArQule presents recent data on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Oct 21, 2019: ArQule announces preclinical data demonstrating potential of Miransertib (ARQ 092) to treat PIK3CA-driven vascular malformations at 2019 ASHG Annual Meeting
Oct 16, 2019: ArQule announces presentations on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Oct 08, 2019: ArQule to Present Preclinical Data on Miransertib for the Treatment of Vascular Malformations at the 2019 American Society of Human Genetics (ASHG) Annual Meeting
Oct 02, 2019: ArQule announces first patient dosed in registrational MOSIAC trial of Miransertib for the treatment of Proteus Syndrome and PIK3CA-related Overgrowth Spectrum
Jun 17, 2019: ArQule announces preliminary results from its phase 1/2 study of Miransertib (ARQ 092), in Patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) in an oral presentation at the European Society of Human Genetics Conference
Jun 10, 2019: ArQule announces oral presentation for its Pan-AKT inhibitor, miransertib, at the 2019 European Society of Human Genetics (ESHG) Conference
Feb 25, 2019: ArQule announces publication of clinical data with Miransertib in Proteus syndrome
Nov 16, 2018: ArQule presents clinical and preclinical data for ARQ 751 at the 30th EORTC/AACR/NCI Symposium
Nov 12, 2018: NCI-MATCH precision medicine cancer trial enrolling 7-8 new patients weekly
Nov 08, 2018: ArQule to present clinical and preclinical data for ARQ 751 at the 30th EORTC/AACR/NCI symposium
Oct 19, 2018: ArQule presents orphan disease clinical data at the American Society of Human Genetics (ASHG) 2018 Annual Meeting for its pan-AKT inhibitor, Miransertib (ARQ 092)
Oct 04, 2018: ArQule to Present Clinical Update for Miransertib in Rare Disease at the American Society of Human Genetics 2018 Annual Meeting
Sep 13, 2018: Miransertib (ARQ 092) granted fast track designation for the treatment of PIK3CA-related overgrowth spectrum (PROS)
May 16, 2018: Merck to Present Poster on M2698 at ASCO 2018
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by ArQule Inc, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Laekna Therapeutics Shanghai Co Ltd, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Merck KGaA, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Prous Institute for Biomedical Research SA, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Dormant Products, H2 2019 (Contd..3), H2 2019
Discontinued Products, H2 2019
List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ArQule Inc
- AstraZeneca Plc
- Laekna Therapeutics Shanghai Co Ltd
- Merck & Co Inc
- Merck KGaA
- Novartis AG
- Prous Institute for Biomedical Research SA
